6Equopean Commission. Radiation protection following iodine-131 therapy (exposures due to out-patients or discharged in-patients) [ J]. Directorate General Environment Nuclear Safety and Civil- Protection, 1998.
3American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. The Ameri- can Thyroid Association Guidelines Taskforce. Revised manage- ment guidelines for patients with thyroid nodules and differentia- ted thyroid cancer[ J]. Thyroid, 2009, 19 ( 11 ) : 1167 - 1214.
4Mazzaferri EL, Kloos RT. Current approaches to primary thera- py for papillary and follicular thyroid cancer[ J ]. J Clin Endocri- nol Metab ,2001,86 : 1447 - 1463.
5Schlumberger MJ. Papillary and follicular thyroid carcinoma [ J ] N Engl! J Med, 1998,338:297 - 306.
6Bilimoria KY, Bentrem DJ, Ko CY,et al. Extent of surgery af- fects survival for papillary thyroid cancer [ J ]. Ann Surg, 2007, 246:375 - 381.
7Bhattacharyya N, Chien W. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carci- noma [ J ]. Ann Otol Rhinol Laryngol, 2006,115 : 607 - 610.
8Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancy in thyroid cancer patients [ J ]. Br J Cancer, 2003, 89:1638 - 1644.
